Lower respiratory tract infection is a major cause of death due to infectious diseases. Despite substantial progress in the detection of pathogens and in therapeutic options, there continue to be major controversies in the clinical management of these infections. The etiological diagnosis is made only in a very small percentage of the cases of community-acquired pneumonia (CAP). Thus, antimicrobial therapy is empirical in the vast majority of cases, and should be based on local epidemiological and surveillance studies.
Pneumonia should be suspected in patients with newly acquired lower respiratory symptoms (cough, sputum production, and/or dyspnea), especially if these symptoms are accompanied by fever, altered breath sounds, and rales. It is recognized that there must be a balance between reasonable diagnostic procedures and empiric therapy. The importance of establishing the diagnosis of pneumonia and its cause is heightened with the increased concern on overuse of antibiotics.
Diagnosis of CAP is based on an analysis of clinical and laboratory data, including chest radiography and microbiological data. The differential diagnosis includes infectious and noninfectious causes. The main examples of noninfectious causes are reactive airways disease, atelectasis, congestive heart failure, bronchiolitis obliterans with organizing pneumonia (BLOOP), vasculitis, pulmonary embolism, and pulmonary malignancy. Patients in risk classes I and II do not usually require hospitalization, those in risk class III may require brief hospitalization, and those in risk classes IV and V usually require hospitalization. Social factors, such as outpatient support mechanisms and probability of adherence, are not included in this assessment.
Prospective studies for evaluating the causes of CAP in adults have failed to identify the cause of 40% to 60% of cases, and two or more etiologies have been identified in 2-5% of cases [Bartlett et al., 1998 Antimicrobial therapy should be chosen based on four main factors: in vitro activity spectrum, adverse reactions, regimen, and cost. Similar to established guidelines, we divided the patients into four groups based on the severity of the infections and the characteristics of the patient (PORT risk classes - Table 1 Notes:
a The newer fluoroquinolones with enhanced antipneumococci activity (gatifloxacin or levofloxacin or moxifloxacin) should be used with caution to avoid rapid increases in resistance rates. The tetracyclines were NOT included in the "preferred antimicrobial agents" list due to high rates of resistance > 20% in Brazil [Sader et The differentiation between CAP caused by "typical" and "atypical" pathogens is extremely difficult based only on clinical symptoms, physical findings, and chest radiography.
C -Therapeutic recommendation for patients that require hospitalization in a general medical ward (risk classes III and IV)
Preferred antimicrobial (no order of preference):
• Intravenous ceftriaxone or cefuroxime plus IV azithromycin or clarithromycin when there is suspicion of "atypical" pneumonia.
• Intravenous fluoroquinolone (gatifloxacin or levofloxacin).
Alternatives:
• Amoxicillin/clavulanate or ampicillin/sulbactam a .
Antimicrobial Therapy for Community-Acquired Pneumonia Ampicillin/sulbactam can be used in this group of patients; however, we suggest reserving this antimicrobial agent mainly to treat infections caused by multiple-drug resistant Acinetobacter spp.
• When there is suspicion of aspiration or when anaerobic bacteria are suspected as the cause of pneumonia (in alcoholized patients, or the elderly with altered mental status) the addition of a drug to treat (cover) anaerobic bacteria such as clindamycin or monotherapy with ampicillin/sulbactam or amoxicillin/ clavulanate, is necessary. Clinical experience with the use of these new fluoroquinolones in the treatment of pneumonia in the ICU is still limited.
D -Therapeutic recommendation for patients that require hospitalization in an intensive care unit (risk classes IV and V)
Rifampin can be added when Legionella species is suspected.
Oxacillin may replace either regimen when oxacillinsusceptible S. aureus is diagnosed as the cause of infections; however, both regimens provide adequate coverage for this pathogen.
Vancomycin should be added when oxacillinresistant S. aureus is suspected. Other options are linezolid and quinopristin/dalfopristin.
Fourth-generation cepholosporins and/or ciprofloxacin and/or an aminoglycoside can be added when Pseudomonas aeruginosa is suspected due to high rates of antimicrobial resistance. P. aeruginosa pneumonia can be treated with drug combinations, but the isolate should be susceptible to the antimicrobial agents used.
